Oligomannate (compound code GV-971) is a first-in-class drug invented and developed in China to improve cognitive function for those with mild to moderate Alzheimer’s disease. It was granted conditional approval by China’s National Medical Products Administration on Nov. 2, 2019 and went on sale Dec. 29. It’s the first new Alzheimer’s drug to go on the market in the last 17 years.  

In addition, several new drugs developed by the Innovation Academy for Drug Discovery and Development of the Chinese Academy of Sciences and other units have recently been approved for clinical trial. They include Simmitinib for cancer therapy and Thioraviroc for HIV treatment. 

Oligomannate, a new, domestically developed Alzheimer's drug